← Back to Screener
Benitec Biopharma Inc. Common Stock (BNTC)
Price$13.46
Favorite Metrics
Price vs S&P 500 (26W)-7.53%
Price vs S&P 500 (4W)10.62%
Market Capitalization$467.22M
All Metrics
Book Value / Share (Quarterly)$3.57
P/TBV (Annual)40.75x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.85
Price vs S&P 500 (YTD)-1.68%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-20671.43%
EPS (TTM)$-1.11
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-1.11
EPS (Annual)$-1.05
ROI (Annual)-46.28%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-16368.59%
Cash / Share (Quarterly)$3.60
ROA (Last FY)-41.83%
EBITD / Share (TTM)$-1.21
ROE (5Y Avg)-2121.74%
Operating Margin (TTM)-20714.29%
Cash Flow / Share (Annual)$-1.96
P/B Ratio4.99x
P/B Ratio (Quarterly)3.93x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)5324.86x
Net Interest Coverage (TTM)-42.47x
ROA (TTM)-44.04%
EPS Incl Extra (Annual)$-1.05
Current Ratio (Annual)10.57x
Quick Ratio (Quarterly)46.72x
3-Month Avg Trading Volume0.17M
52-Week Price Return2.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)5840.24x
Asset Turnover (Annual)0.02x
52-Week High$17.15
Operating Margin (5Y Avg)-16055.53%
EPS Excl Extra (Annual)$-1.05
CapEx CAGR (5Y)-29.03%
Tangible BV CAGR (5Y)-57.08%
26-Week Price Return-3.55%
Quick Ratio (Annual)10.46x
13-Week Price Return12.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)46.95x
Enterprise Value$372.74
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-33.13%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-24450.00%
Cash / Share (Annual)$5.10
3-Month Return Std Dev57.09%
Gross Margin (5Y Avg)94.40%
Net Income / Employee (TTM)$-2
ROE (Last FY)-46.28%
Net Interest Coverage (Annual)-68.59x
EPS Basic Excl Extra (Annual)$-1.05
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.11
Receivables Turnover (Annual)2.67x
ROI (TTM)-45.91%
P/S Ratio (TTM)6674.56x
Pretax Margin (5Y Avg)-16368.59%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.12
Price vs S&P 500 (52W)-27.34%
Year-to-Date Return0.97%
5-Day Price Return23.52%
EPS Normalized (Annual)$-1.05
ROA (5Y Avg)-184.34%
Net Profit Margin (Annual)-24450.00%
Month-to-Date Return27.70%
Cash Flow / Share (TTM)$-14.00
EBITD / Share (Annual)$-1.13
Operating Margin (Annual)-23850.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-2121.74%
EPS Basic Excl Extra (TTM)$-1.11
P/TBV (Quarterly)40.75x
P/B Ratio (Annual)1.45x
Pretax Margin (TTM)-20671.43%
Book Value / Share (Annual)$4.70
Price vs S&P 500 (13W)11.34%
Beta0.37x
P/FCF (Annual)123.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-45.91%
52-Week Low$9.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BNTCBenitec Biopharma Inc. Common Stock | 6674.56x | — | 100.00% | — | $13.46 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines designed to provide one-time curative treatments. The company's lead program, BB-301, is a silence-and-replace therapeutic targeting Oculopharyngeal Muscular Dystrophy (OPMD), a rare, chronic genetic disorder with no currently effective treatments.